FI3999180T3 - (r)-n-(5-(5-etyyli-1,2,4-oksadiatsol-3-yyli)-2,3-dihydro-1h-inden-1–yyli)-1–metyyli-1h-pyratsoli-4-karboksamidin polymorfeja - Google Patents

(r)-n-(5-(5-etyyli-1,2,4-oksadiatsol-3-yyli)-2,3-dihydro-1h-inden-1–yyli)-1–metyyli-1h-pyratsoli-4-karboksamidin polymorfeja Download PDF

Info

Publication number
FI3999180T3
FI3999180T3 FIEP20753562.6T FI20753562T FI3999180T3 FI 3999180 T3 FI3999180 T3 FI 3999180T3 FI 20753562 T FI20753562 T FI 20753562T FI 3999180 T3 FI3999180 T3 FI 3999180T3
Authority
FI
Finland
Prior art keywords
polymorph
polymorphic form
peaks
degrees
xrpd pattern
Prior art date
Application number
FIEP20753562.6T
Other languages
English (en)
Finnish (fi)
Inventor
Norma TOM
Matthew Pfeiffer
Denise Andersen
Qi Gao
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71995103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI3999180(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Application granted granted Critical
Publication of FI3999180T3 publication Critical patent/FI3999180T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
FIEP20753562.6T 2019-07-17 2020-07-16 (r)-n-(5-(5-etyyli-1,2,4-oksadiatsol-3-yyli)-2,3-dihydro-1h-inden-1–yyli)-1–metyyli-1h-pyratsoli-4-karboksamidin polymorfeja FI3999180T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962875350P 2019-07-17 2019-07-17
PCT/US2020/042387 WO2021011807A1 (en) 2019-07-17 2020-07-16 Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide

Publications (1)

Publication Number Publication Date
FI3999180T3 true FI3999180T3 (fi) 2024-06-18

Family

ID=71995103

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP20753562.6T FI3999180T3 (fi) 2019-07-17 2020-07-16 (r)-n-(5-(5-etyyli-1,2,4-oksadiatsol-3-yyli)-2,3-dihydro-1h-inden-1–yyli)-1–metyyli-1h-pyratsoli-4-karboksamidin polymorfeja

Country Status (25)

Country Link
US (1) US20220315571A1 (cg-RX-API-DMAC10.html)
EP (2) EP4487911A1 (cg-RX-API-DMAC10.html)
JP (2) JP7624431B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220084008A (cg-RX-API-DMAC10.html)
CN (3) CN118908951A (cg-RX-API-DMAC10.html)
AU (1) AU2020313965B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022000494A2 (cg-RX-API-DMAC10.html)
CA (1) CA3144975A1 (cg-RX-API-DMAC10.html)
CL (1) CL2022000054A1 (cg-RX-API-DMAC10.html)
DK (1) DK3999180T3 (cg-RX-API-DMAC10.html)
ES (1) ES2980885T3 (cg-RX-API-DMAC10.html)
FI (1) FI3999180T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20240713T1 (cg-RX-API-DMAC10.html)
HU (1) HUE066891T2 (cg-RX-API-DMAC10.html)
IL (1) IL289875B1 (cg-RX-API-DMAC10.html)
LT (1) LT3999180T (cg-RX-API-DMAC10.html)
MX (1) MX2022000504A (cg-RX-API-DMAC10.html)
PH (1) PH12022550123A1 (cg-RX-API-DMAC10.html)
PL (1) PL3999180T3 (cg-RX-API-DMAC10.html)
PT (1) PT3999180T (cg-RX-API-DMAC10.html)
RS (1) RS65611B1 (cg-RX-API-DMAC10.html)
SI (1) SI3999180T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202400224T1 (cg-RX-API-DMAC10.html)
TW (1) TWI865562B (cg-RX-API-DMAC10.html)
WO (1) WO2021011807A1 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202006296YA (en) 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
MX2022000498A (es) 2019-07-17 2022-02-03 Cytokinetics Inc Polimorfos de (r)-n-(5-(5-isopropil-1,2,4-oxadiazol-3-il)-2,3-dihi dro-1h-inden-1-il) -2-metil-2h- tetrazol-5-carboxamida.
KR20240015622A (ko) 2021-03-04 2024-02-05 싸이토키네틱스, 인코포레이티드 심장 근절 억제제
EP4370116B1 (en) 2021-07-16 2025-01-15 Cytokinetics, Inc. Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy
JP2024530111A (ja) 2021-08-03 2024-08-16 サイトキネティックス, インコーポレイテッド アフィカムテンを調製するための工程
US20240091203A1 (en) 2022-07-20 2024-03-21 Cytokinetics, Incorporated Methods for treating non-obstructive hypertrophic cardiomyopathy
JP2025525913A (ja) 2022-08-04 2025-08-07 サイトキネティックス, インコーポレイテッド 閉塞性肥大型心筋症を治療するための方法
WO2024134498A1 (en) 2022-12-22 2024-06-27 Assia Chemical Industries Ltd. Solid state forms of aficamten and process for preparation thereof
CN120712262A (zh) * 2023-03-02 2025-09-26 苏州科睿思制药有限公司 Aficamten的共晶及其制备方法和用途
WO2025198687A1 (en) 2024-03-20 2025-09-25 Cytokinetics, Incorporated Methods for treating heart diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202006296YA (en) * 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP2024530111A (ja) * 2021-08-03 2024-08-16 サイトキネティックス, インコーポレイテッド アフィカムテンを調製するための工程

Also Published As

Publication number Publication date
IL289875B1 (en) 2026-05-01
CA3144975A1 (en) 2021-01-21
NZ784930A (en) 2025-03-28
IL289875A (en) 2022-03-01
EP4487911A1 (en) 2025-01-08
EP3999180B1 (en) 2024-05-08
JP2022540668A (ja) 2022-09-16
KR20220084008A (ko) 2022-06-21
TWI865562B (zh) 2024-12-11
CN114555590A (zh) 2022-05-27
CN118908951A (zh) 2024-11-08
ES2980885T3 (es) 2024-10-03
JP2025061484A (ja) 2025-04-10
HRP20240713T1 (hr) 2024-09-13
EP3999180A1 (en) 2022-05-25
MX2022000504A (es) 2022-02-10
US20220315571A1 (en) 2022-10-06
CN114555590B (zh) 2024-09-10
BR112022000494A2 (pt) 2022-03-03
PH12022550123A1 (en) 2022-12-19
JP7755090B2 (ja) 2025-10-15
PT3999180T (pt) 2024-06-25
AU2020313965B2 (en) 2026-06-18
AU2020313965A1 (en) 2022-03-03
CL2022000054A1 (es) 2022-10-07
LT3999180T (lt) 2024-08-26
JP7624431B2 (ja) 2025-01-30
PL3999180T3 (pl) 2024-09-23
WO2021011807A1 (en) 2021-01-21
DK3999180T3 (da) 2024-05-21
RS65611B1 (sr) 2024-07-31
SMT202400224T1 (it) 2024-07-09
TW202116763A (zh) 2021-05-01
SI3999180T1 (sl) 2024-07-31
HUE066891T2 (hu) 2024-09-28
CN119119018A (zh) 2024-12-13

Similar Documents

Publication Publication Date Title
HRP20240713T1 (hr) Polimorfi od (r)-n-(5-(5-etil-1,2,4-oksadiazol-3-il)-2,3-dihidro-1h-inden- 1-il)-1-metil-1h-pirazol-4-karboksamida
JP2022540668A5 (cg-RX-API-DMAC10.html)
TWI313264B (en) Triamide-substituted heterobicyclic compounds
JP5237324B2 (ja) セロトニン様作用薬としてのインダゾールアミド化合物
HK1244694A1 (zh) 新颖的胰高血糖素受体拮抗剂
JPH08508034A (ja) フェノキシフェニル酢酸誘導体
JPWO2001064670A1 (ja) 新規環状アミド誘導体
TWI600658B (zh) 醛固酮合成酶抑制劑
WO2007129745A1 (ja) ヘテロアリールアミド低級カルボン酸誘導体
JP2004043453A (ja) (s)−4−アミノ−5−クロロ−2−メトキシ−n−[1−[1−(2−テトラヒドロフリルカルボニル)−4−ピペリジニルメチル]−4−ピペリジニル]ベンズアミド、その製造方法、それを含有する医薬組成物及び該化合物の中間体
EP3053916A1 (en) Compound having agonistic activity to somatostatin receptor and medicinal use thereof
CN110357789B (zh) 作为dhodh抑制剂的n-取代丙烯酰胺衍生物及其制备和用途
AU2018387747A1 (en) Substituted pyrrolidine amides II
EP1507763A1 (de) Tetrahydroisochinolin-derivate
JP2022542803A5 (cg-RX-API-DMAC10.html)
WO2008050732A1 (fr) Dérivé de l'iminopyridine et son utilisation
JP7273722B2 (ja) タウオリゴマーの形成を阻害する新規ベンゾフラン、ベンゾチオフェン及びインドール類似体並びにそれらの使用方法
JP2000505461A (ja) 胃運動機能調整特性を有する新規n―置換4―((4’―アミノベンゾイル)オキシメチル)ピペリジン類
WO2004046107A1 (en) Indole derivatives as somatostatin agonists or antagonists
TWI331142B (cg-RX-API-DMAC10.html)
JP4511184B2 (ja) オキシトシン・アンタゴニストとしてのトリアゾール類
KR20180095594A (ko) 인단 유도체 및 가용성 구아닐레이트 시클라제 활성화제로서의 그의 용도
KR20100042671A (ko) 신규 페닐아세테이트 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 t-형 칼슘 이온 채널의 활성에 의해 유발되는 질환의 예방 또는 치료용 조성물
CA3008698C (en) Ginkgolide b derivative and preparation method and use thereof
JP2005526816A (ja) 抗ヒスタミン薬および抗アレルギー薬としてのアザインドリルピペリジン誘導体